He Shoots and He Scores. Dicerna (DRNA) up 78%.
Our Second $3.00 Watch List Company Gets Acquired for Over $1 Billion. As They say "You Can't Make This **** Up."
And We Have Our First MEME Stock! $2.00 to $29.95.
Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg) Guess we were bound to stumble across...
ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites
Gentleman, Start Your Engines? ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).
Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal. We've had...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News